Controlled	Award Principal Investigator		Award Organization	Sponsor Name	Award Name	Award Start Date	Award End Date	Funded Amount	Total Award Amount
Section Continue			Name						
Column	Monteleone	Philip	110 Pediatrics	Bristol Myers Squibb Company	extrapolated efficacy study in pediatric Subjects requiring anticoagulation for the treatment of a venous thromboembolic	17-Sep-2018	16-Sep-2019	9,750.00	9,750.00
Bragatis with Formation of Academics of Section (1997) Bragatis with Formation (1997) Bragatis with Section (1997) B	Lavelle	William		Innovasis Incorporated		11-Sep-2018	10-Sep-2019	12,500.00	12,500.00
	Cohen	Stephen	110 OB/GYN	AbbVie Incorporated	Elagolix with Hormonal Add-Back in Subjects with	01-Jun-2018	31-May-2019	1.00	1.00
Description	Gahtan	Vivian		Eastern Vascular Society	2018 EVS Research Seed Grant Fellowship for Dr. Furqan Muqri	02-Sep-2018	01-Sep-2019	25,000.00	25,000.00
March	Domachowske	Joseph		Merck Sharp and Dohme Corporation	Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term	17-Sep-2018	16-Sep-2019	24,423.06	24,423.06
Medicane 130 Predictors 130 Predic	Weinstock	Ruth	110 Medicine	Joslin Diabetes Center	Preventing Early Rental Loss Follow-up Study (PERLage)	01-Jun-2018	31-Oct-2020	1.00	1.00
Septem 110 Psychiatry 110 Medicine 110 Medi	Endy	Timothy	110 Microbiology	Advanced Technology International	Dengue Human Infection Model	20-Sep-2018	25-Oct-2019	201,709.00	201,709.00
Sephen 110 Medicine	Comito	Melanie	110 Pediatrics	St Baldricks Foundation	St. Baldrick's Infrastructure Grant 2018	01-Dec-2018	30-Nov-2019	59,075.00	59,075.00
Freedrick 10 Mercebiology University of Rinde Labard Residuous Interfections: Pathogenesis and Prevention 13-Jug-2015 32-Jul-2019 17,096.00 17,096	Schwartz	Thomas	110 Psychiatry			01-Sep-2018	30-Aug-2020	50,000.00	100,000.00
Autor Martin Fetch Tammy 10 Dean - College Insalth Science Center Foundation at College of Nursing 13 Am 2018 30 Am 2018 30 Am 2019 2,000 0 2,000 0 2,000 0 7,000	Graziano	Stephen	110 Medicine	0,	Alliance Cooperative Studies	01-Oct-2018	30-Sep-2019	6,800.00	6,800.00
Thomas Stephen 110 Medicine University of fibode Island Flavinus infections: Pathogenesis and Prevention 13-Aug-2018 31-1u-2019 24,951.00 24,951	Endy	Timothy	110 Microbiology	University of Rhode Island	Flavivirus Infections: Pathogenesis and Prevention	13-Aug-2018	31-Jul-2019	117,009.00	117,009.00
Carry	Austin-Ketch	Tammy			College of Nursing	01-Jun-2018	30-Jun-2019	2,000.00	2,000.00
Infectious Disease	Thomas	Stephen	110 Medicine	University of Rhode Island	Flavivirus Infections: Pathogenesis and Prevention	13-Aug-2018	31-Jul-2019	24,951.00	24,951.00
Milliam 130 Microbiology University of Kentucky Research Parasisting SHPS Genetics to Generate a Novel Alzheimers 15-Sep-2018 31-Juz-2019 187,20.00	Chan	Gary	110 Microbiology		I	09-Nov-2018	31-Oct-2019	571,406.00	2,689,846.00
Find	Kerr	William	110 Microbiology	University of Kentucky Research	Translating SHIP1 Genetics to Generate a Novel Alzheimers	15-Sep-2018	30-Jun-2019	187,202.00	187,202.00
1-10 1.0 Psychiatry Veterans Affairs Medical Center Integoperamental Personnel Agreement for Karen Hughes 30-Nov-2018 37-Nov-2020 108,434.00 108,	Endy	Timothy	110 Microbiology		Janssen Global Public Health Project Support Services	01-Sep-2018	31-Aug-2019	145,600.00	145,600.00
Domachowske Joseph Jose	Zhao	Li-Ru	110 Psychiatry	Veterans Affairs Medical Center		30-Nov-2018	29-Nov-2020	108,434.00	108,434.00
Domachowske Joseph 110 Pediatrics Merck Sharp and Dohme Corporation A Phase 3, Multicenter, Rapidlary (110 Surgery Call Control of Call Call Enter Here Changeability (110 Surgery Call Call Call Call Call Call Call Cal	Cosgrove	Michael	110 Biochemistry	Syracuse University	_	01-Jun-2018	31-May-2019	42,149.00	42,149.00
Cunningham Mary 110 OB/GYN Vascular Biogenics Ltd The OVAL Study: A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer Kevin 110 Surgery - Orthopedics Plana Coporate S.p.A. Retrospective clinical study analyzing outcomes of anatomic shoulder arthroplasty with SMR Metal Back glenoid and SMR TT Plana Cology Research Fund Inc Predictive biomarkers for Hsp90 drugs activity in breast cancer Unology Research Fund Inc Predictive biomarkers for Hsp90 drugs activity in breast cancer Investigation of RBEL1A in Human Breast Cancer Research Fund Inc Predictive biomarkers for Hsp90 drugs activity in breast cancer Investigation of RBEL1A in Human Breast Cancer Research Fund Inc Predictive biomarkers for Hsp90 drugs activity in Dream Cancer Investigation of RBEL1A in Human Breast Cancer Research Fund Inc Predictive biomarkers for Hsp90 drugs activity in Dream Cancer Investigation of RBEL1A in Human Breast Cancer Research Fund Inc Predictive biomarkers for Hsp90 drugs activity in Dream Cancer Investigation of RBEL1A in Human Breast Cancer Research Fund Inc Predictive biomarkers for Hsp90 drugs activity in Dream Cancer Investigation of RBEL1A in Human Breast Cancer Research Fund Inc Predictive biomarkers for Hsp90 drugs activity in Dream Cancer Investigation of RBEL1A in Human Breast Cancer Research Fund Inc Predictive biomarkers for Hsp90 drugs activity in Dream Cancer Investigation of RBEL1A in Human Breast Cancer Research Fund Inc Predictive biomarkers for Hsp90 drugs activity in Dream Cancer Investigation of RBEL1A in Human Breast Cancer Research Fund Inc Predictive biomarkers for Hsp90 drugs activity in Dream Cancer Investigation of RBEL1A in Human Breast Cancer Research Fund Inc Predictive biomarkers for Hsp90 drugs activity in Dream Cancer Investigation of RBEL1A in Human Breast Cancer Investigation of RBEL1A in Human Breast Cancer Investigation of RBEL1A	Domachowske	Joseph	110 Pediatrics	Merck Sharp and Dohme Corporation	A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13(TM) with Respect to Safety, Tolerability, and Immunogenicity in	01-Oct-2018	30-Sep-2019	1.00	1.00
Cunningham Mary 110 OB/GYN Vascular Biogenics Ltd 1 The OVAL Study: A Bandomized, Controlled, Double-Arm, Open- 04-May-2018 03-May-2019 1.00 1.0	Werner	Frederick		Stryker Orthopaedics		01-Sep-2018	31-Aug-2020	17,754.00	17,754.00
Mollapour Mehdi 110 Surgery - Carol M. Baldwin Breast Cancer Predictive biomarkers for Hsp90 drugs activity in breast cancer O1-Dec-2018 30-Nov-2020 50,000.00	Cunningham	Mary		Vascular Biogenics Ltd	The OVAL Study: A Randomized, Controlled, Double-Arm, Open- Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs Paclitaxel Monotherapy for the		03-May-2019	1.00	1.00
Huang Ying 110 Pharmacology Carol M. Baldwin Breast Cancer Research Fund Inc King Christine 110 Microbiology Carol M. Baldwin Breast Cancer Research Fund Inc Turner Christopher 110 Cell & Developmental Biology Ceneral University of Vermont Ceneral University of Vermont University of Ve	Setter	Kevin		LimaCoporate S.p.A.	shoulder arthroplasty with SMR Metal Back glenoid and SMR TT	13-Nov-2018	12-Dec-2019	1.00	1.00
Huang Ying 110 Pharmacology Carol M. Baldwin Breast Cancer Research Fund Inc King Christine 110 Microbiology Carol M. Baldwin Breast Cancer Research Fund Inc King Christine 110 Microbiology Carol M. Baldwin Breast Cancer Research Fund Inc Turner Christopher 110 Cell & Developmental Biology Nieman Gary 110 Surgery - General Line Yingxi 110 Psychiatry Program Org Cunningham Mary 110 OB/GYN Clovis Oncology Incorporated A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rusaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) Bah Alaji 110 Biochemistry Carol M. Baldwin Breast Cancer Research Fund Inc Investigation of RBEL1A in Human Breast Cancer Research Cancer Research Fund Inc KX signaling in STAT3-driven breast cancer 01-Dec-2018 30-Nov-2020 50,000.00 50,000.00 D1-Dec-2018 30-Nov-2020 50,000.00 D1-Dec-2018 30-Nov-202	Mollapour	Mehdi			Predictive biomarkers for Hsp90 drugs activity in breast cancer	01-Dec-2018	30-Nov-2020	50,000.00	50,000.00
King Christine 110 Microbiology Research Fund Inc Research Fund Inc Carol M. Baldwin Breast Cancer Research Fund Inc Research Fund Inc Developmental Biology University of Vermont Preserving Epithelial Barrier Integrity in Ventilator-Induced Uning Injury University of Vermont Uning Injury University of Vermont Uning Injury Preserving Epithelial Barrier Integrity in Ventilator-Induced Uning Injury University of Vermont University of Vermo	Huang	Ying		Carol M. Baldwin Breast Cancer	Investigation of RBEL1A in Human Breast Cancer	01-Dec-2018	30-Nov-2020	50,000.00	50,000.00
Turner Christopher 110 Cell & Developmental Biology Nieman Gary 110 Surgery - General Ling Injury Lin Yingxi 110 Psychiatry Program Org Cunningham Mary 110 OB/GYN Clovis Oncology Incorporated A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) Bah Alaji 110 Biochemistry Carol M. Baldwin Breast Cancer Targeting the Phase Separation of MBDs in Breast Cancer O1-Dec-2018 30-Nov-2020 50,000.00 5	King	Christine	110 Microbiology	Carol M. Baldwin Breast Cancer	K2 signaling in STAT3-driven breast cancer	01-Dec-2018	30-Nov-2020	50,000.00	50,000.00
Nieman Gary 110 Surgery - General University of Vermont Preserving Epithelial Barrier Integrity in Ventilator-Induced University of Vermont University of Vermont University of Vermont Preserving Epithelial Barrier Integrity in Ventilator-Induced University of Vermont University of Vermont Preserving Epithelial Barrier Integrity in Ventilator-Induced University of Vermont University of Vermont University of Vermont Preserving Epithelial Barrier Integrity in Ventilator-Induced University of Vermont Preserving Epithelial Barrier Integrity in Ventilator-Induced University of Vermont Universi	Turner	Christopher	Developmental	Carol M. Baldwin Breast Cancer	Role of Hic-5 in Breast Tumor Stromal Matrix Remodeling	01-Dec-2018	30-Nov-2020	50,000.00	50,000.00
Lin Yingxi 110 Psychiatry International Human Frontier Science Fellowship for Jian Xue 16-Nov-2018 15-Nov-2019 25,664.50 25,664.50 Cunningham Mary 110 OB/GYN Clovis Oncology Incorporated Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) 21-Aug-2019 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1	Nieman	Gary	110 Surgery -	University of Vermont		01-Sep-2018	30-Jun-2019	194,104.00	194,104.00
Cunningham Mary 110 OB/GYN Clovis Oncology Incorporated A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) Bah Alaji 110 Biochemistry Carol M. Baldwin Breast Cancer Targeting the Phase Separation of MBDs in Breast Cancer 01-Dec-2018 30-Nov-2020 50,000.00 50,000.00	Lin	Yingxi				16-Nov-2018	15-Nov-2019	25,664.50	25,664.50
	Cunningham	·	110 OB/GYN		Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response	22-Aug-2018		1.00	1.00
	Bah	Alaji	110 Biochemistry	Carol M. Baldwin Breast Cancer Research Fund Inc	Targeting the Phase Separation of MBDs in Breast Cancer	01-Dec-2018	30-Nov-2020	50,000.00	50,000.00